Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 212-883-4330

Website: www.hypestrat.xyz

Address:

477 Madison Avenue, 22nd Floor, New York, United States

theta_cat_purrs May. 12 at 8:33 PM

$PURR This is dead now with the ETF.

0 · Reply

Jackie_Treehorn May. 9 at 1:41 AM

$PURR https://youtu.be/CSWPGeNfKRA?si=yYsgWstlXkwAJIv4

0 · Reply

MarketBeat May. 8 at 10:15 PM

Hyperliquid Strategies Q3 Earnings Call Highlights $PURR https://www.marketbeat.com/instant-alerts/hyperliquid-strategies-q3-earnings-call-

0 · Reply

HelptheMarkets May. 8 at 7:00 PM

$PURR you guys are still letting me DCA cheap! Thanks!

0 · Reply

PedroBallante May. 8 at 1:00 PM

$PURR NO debt - still got a strong 3 months to go to year end.. with a coin price that has improved and Oil & Perps over weekends during Iran - Let's take it high!

1 · Reply

PedroBallante May. 7 at 11:12 PM

$PURR Quarter net profit at 152.5M!! still got 3 months to got to take us into profit, helped in part by Perps traded over weekends.... //www.stocktitan.net/news/PURR/hyperliquid-strategies-inc-reports-financial-results-for-the-quarter-lff2imzjcbid.html

1 · Reply

Options May. 7 at 8:35 PM

The markets are hitting all-time highs and Henry "The Flowmaster" Schwartz from Cboe has the data on why contract volume is exploding. Check out "The Option Block 1467: Live from #OptionsConf2026." Inside the episode: ✅ Is this rally sustainable? ✅ State of the Industry deep dive ✅ Unusual activity in $GAMB, $PURR, and $CTSH Listen now on your favorite podcast platform or here: http://traffic.libsyn.com/radionetwork/OB_5-7-26__-_FINAL.mp3

0 · Reply

PedroBallante May. 7 at 7:43 PM

$PURR its oh so quiet....

0 · Reply

Bellaire May. 7 at 4:43 PM

$PURR I think they’re trying to shake out people here hold on to your shares

1 · Reply

PedroBallante May. 7 at 3:24 PM

$PURR people's thoughts around earnings being priced in?

0 · Reply

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

May 7, 2026, 5:00 PM EDT - 5 days ago

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

2026-05-07T20:47:48.000Z - 5 days ago

Hyperliquid Strategies, Unit Labs announce validator on Hyperliquid

May 7, 2026, 4:15 PM EDT - 5 days ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 5 days ago

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

Apr 28, 2026, 4:15 PM EDT - 14 days ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

2026-04-24T12:14:26.000Z - 19 days ago

Hyperliquid Strategies initiated with a Buy at Maxim

2026-04-24T12:06:12.000Z - 19 days ago

Hyperliquid Strategies initiated with a Buy at Maxim

2026-03-24T20:21:02.000Z - 7 weeks ago

Hyperliquid Strategies begins trading options in Nasdaq Options Market

Mar 24, 2026, 4:15 PM EDT - 7 weeks ago

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

2026-03-24T12:37:38.000Z - 7 weeks ago

One new option listing and sixteen option delistings on March 24th

2026-02-12T13:51:22.000Z - 3 months ago

Hyperliquid Strategies price target raised to $6 from $5 at Cantor Fitzgerald

Feb 11, 2026, 8:00 AM EST - 3 months ago

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Feb 11, 2026, 6:45 AM EST - 3 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 3 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

2025-12-24T09:35:33.000Z - 5 months ago

Hyperliquid Strategies initiated with a Buy at Chardan

2025-12-16T14:47:06.000Z - 5 months ago

Cantor starts Hyperliquid treasury company Hyperliquid Strategies at Overweight

2025-12-16T11:45:10.000Z - 5 months ago

Hyperliquid Strategies initiated with an Overweight at Cantor Fitzgerald

Dec 8, 2025, 9:20 AM EST - 5 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 5 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 5 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 6 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Oct 15, 2025, 10:03 AM EDT - 7 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 8 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 9 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 10 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 6:00 AM EDT - 10 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

theta_cat_purrs May. 12 at 8:33 PM

$PURR This is dead now with the ETF.

0 · Reply

Jackie_Treehorn May. 9 at 1:41 AM

$PURR https://youtu.be/CSWPGeNfKRA?si=yYsgWstlXkwAJIv4

0 · Reply

MarketBeat May. 8 at 10:15 PM

Hyperliquid Strategies Q3 Earnings Call Highlights $PURR https://www.marketbeat.com/instant-alerts/hyperliquid-strategies-q3-earnings-call-

0 · Reply

HelptheMarkets May. 8 at 7:00 PM

$PURR you guys are still letting me DCA cheap! Thanks!

0 · Reply

PedroBallante May. 8 at 1:00 PM

$PURR NO debt - still got a strong 3 months to go to year end.. with a coin price that has improved and Oil & Perps over weekends during Iran - Let's take it high!

1 · Reply

PedroBallante May. 7 at 11:12 PM

1 · Reply

Options May. 7 at 8:35 PM

0 · Reply

PedroBallante May. 7 at 7:43 PM

$PURR its oh so quiet....

0 · Reply

Bellaire May. 7 at 4:43 PM

$PURR I think they’re trying to shake out people here hold on to your shares

1 · Reply

PedroBallante May. 7 at 3:24 PM

$PURR people's thoughts around earnings being priced in?

0 · Reply

RichardFatCock May. 7 at 2:37 PM

$PURR just opened a nice position here recomended by a friend. Looking forward to 5-10x!

0 · Reply

WestEgg May. 7 at 2:34 PM

$PURR let’s go all you Yalies at PURR- looking forward to $10-$20 per share.

0 · Reply

Thelonius_Stonk May. 7 at 2:08 PM

$PURR baller

1 · Reply

goalseeker May. 7 at 1:34 PM

$PURR LETS GO $7:00 clap 👏 clap !👏

0 · Reply

goalseeker May. 7 at 1:34 PM

$PURR LETS GO GREEN$!

0 · Reply

keykoolcat May. 7 at 11:49 AM

$PURR What's group members' feelings about holding through earnings - AMC 07May (ah, today)? Long, up 12%.

0 · Reply

Mg_1970 May. 7 at 1:29 AM

$PURR I still keep my positions for a long term period 🤞😎💪 $7 is a key level.

0 · Reply

Stoxpo May. 6 at 11:30 PM

$PURR - Formerly a biotech company, this is now a digital treasury asset company that is accumulating the HYPE token, one of the top performing digital assets. The company also entered into a strategic collaboration with Kalshi to merge decentralized infrastructure with regulated prediction markets. The company reports earnings tomorrow after the close and has been consistently trading inside a rising parallel channel. $JOBY - The company rose today off a better than expected earnings report and is on its way to fill a gap from January. Though the price may struggle to recapture the 200 Day SMA, the company reporting that it has achieved full FAA type certification will more likely send the price over that moving average

0 · Reply

YorkMeister May. 6 at 1:28 PM

$HYPD please explain this pricing soon. This was already at a 50% NAV discount and the hypd story is one of a superior model for revenue creation, not a straightforward hype treasury company . Show why this is a good investment thesis , compared to $PURR which is up 80% from February lows of hypx while raising funds.

1 · Reply

Thelonius_Stonk May. 6 at 12:03 PM

$PURR tryna break to new highs

0 · Reply

YorkMeister May. 6 at 8:50 AM

$HYPD still like the model here,and the HYPX potential. But guys, build your brand with investors. Big NAV discount costs you money, you probably could have raised in the 6s by now. And bought HYPX at a better price. This is part of your business model, comma are key. Just dumping an ATM notice without figures or explanation ? Anyway, back to swing trading part of this one and shift some to $PURR which has bob diamond running the story (=good)

0 · Reply

Market Cap	809.51M
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	5,657,900
Avg Vol	5,989,848
Day's Range	N/A - N/A
Shares Out	123.97M
Stochastic %K	39%
Beta	1.44
Analysts	Strong Sell
Price Target	$8.82